The treatment of advanced non small-cell lung cancer
|
|
- Helena Clarke
- 6 years ago
- Views:
Transcription
1 Brief Report PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non Small-Cell Lung Cancer Denis Soulières, MD,* Fred R. Hirsch, MD, PhD, Frances A. Shepherd, MD, Walter Bordogna, PhD, Paul Delmar, PhD, David S. Shames, PhD,# and Barbara Klughammer, PhD# Introduction: EGFR mutations and anaplastic lymphoma kinase rearrangements are, to date, the only approved biomarkers to select treatment for non small-cell lung cancer (NSCLC). However, there is considerable interest in identifying other predictive markers. The PTPRF gene has been suggested as a marker of interest in NSCLC and other tumor types. Methods: This hypothesis-generating retrospective analysis examined data from two studies of erlotinib in NSCLC, Marker Identification Trial (MERIT; n = 102) and Sequential Tarceva in Unresectable NSCLC (SATURN; n = 262), to determine whether PTPRF expression was prognostic and/or predictive of patient outcomes. Exploratory analyses were conducted using quantitative reverse transcription polymerase chain reaction on existing formalin-fixed paraffin-embedded samples, to assess gene expression levels, including PTPRF. High versus low levels of expression were dichotomized using the median with B2M as a control comparator. Progression-free survival and overall survival were then compared for patients with high versus low levels of PTPRF in the two studies. Results: PTPRF expression was found to be prognostic for shorter overall survival but was also significantly predictive of improved survival with erlotinib versus placebo in SATURN (hazard ratio, 0.45 [95% confidence interval, CI, ] in PTPRF high versus 0.96 [95% CI, ] in PTPRF low; interaction p = 0.02), even in the EGFR wild-type subpopulation (adjusted hazard ratio, 0.44 [95% CI, ] versus 0.96 [95% CI, ]; interaction p = 0.01). *Department of Hematology, Centre Hospitalier de l Université de Montréal, Montréal, Canada; Department of Medicine, University of Colorado Cancer Center, Aurora, Colorado; Department of Medicine, University Health Network, Princess Margaret Cancer Centre, Toronto, Canada; Departments of Clinical Science, and Statistics, F. Hoffmann-La Roche Ltd, Basel, Switzerland; and #Department of Oncology Biomarkers, Genentech, Inc., SanFrancisco, California Disclosures: Support for third-party writing support was provided by F. Hoffmann-La Roche Ltd. Drs. Klughammer, Bordogna, and Delmar are employees of F. Hoffmann-La Roche Ltd; Dr. Shames is an employee of Genentech; Dr. Hirsch has received grants and consultancy fees from Genentech; Dr. Shepherd has received consultancy fees and honoraria from F. Hoffmann-La Roche Ltd; Dr. Soulières has received payment for lectures and fees for participation of review activities from F. Hoffmann-La Roche Ltd. Address for correspondence: Barbara Klughammer, F. Hoffmann-La Roche Ltd, Basel, Switzerland. barbara.klughammer@roche.com DOI: /JTO ISSN: /15/ Conclusions: PTPRF may have value as a predictive marker to identify which patients can obtain the greatest benefit from erlotinib in the post first-line setting. Further research is warranted to determine the potential value of this marker in clinical decision-making. Key Words: Erlotinib, Non small-cell lung cancer, Biomarkers, Protein tyrosine phosphatase, PTPRF. (J Thorac Oncol. 2015;10: ) The treatment of advanced non small-cell lung cancer (NSCLC) has been transformed by the advent of targeted therapies with defined biomarkers. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) provide significant progression-free survival (PFS) benefits as first-line treatment for EGFR mutation-positive NSCLC, 1 3 but other exploratory subgroup analyses have suggested that some patients with wild-type EGFR also derive clinical benefit from erlotinib, as demonstrated in studies of unselected patients. 4,5 Approximately 70% to 85% of patients with stage IIIB/IV NSCLC have double-negative tumors, without either an ALK rearrangement or an EGFR mutation. These patients receive generic treatment not tailored to their individual disease, except for the use of histology to exclude specific chemotherapy agents. With the goal being to provide the most effective therapy in the era of molecularly defined lung cancer, the oncology community continues to look for new predictive biomarkers to identify cost-effective treatments for doublenegative patients, across all lines of therapy. One potential marker is the protein tyrosine phosphatase (PTP) receptor type F (PTPRF, sometimes called LAR), which plays a key role in regulating EGFR signaling, by dephosphorylating key tyrosine residues on the receptor. 6,7 Aberrations in the PTP gene family are reported as carcinogenic in numerous solid tumors, including head and neck, prostate and breast cancers. Müller et al. 8 concluded that loss of PTPRF expression could lead to malignancy. A recent study found that high expression of PTPRF was associated with decreased levels of phosphorylated EGFR in breast cancer, which resulted in reduced cell invasion, migration, and metastasis. 9 In contrast, expression of PTPRF is upregulated in some breast cancer tissues compared with controls and has been associated with increased metastatic potential in animal 1364 Journal of Thoracic Oncology Volume 10, Number 9, September 2015
2 Journal of Thoracic Oncology Volume 10, Number 9, September 2015 PTPRF Expression as a Marker for Erlotinib in NSCLC models. 10 The role of PTPRF in tumorigenesis and metastatic behavior remains unclear and may depend on its effect on the expression of other proteins in different tumor types. In lung cancer, specifically, the PTP gene family is of great interest in NSCLC 11,12 and other tumor types, with 107 PTPs identified in the human genome. 13 Motiwala et al. 11 found that overexpression of PTPRO appeared to lead to suppression of growth and increased susceptibility to apoptosis in the A549 lung cancer cell line, whereas Scrima et al. 12 found that mrna expression of PTPRF, along with that of PTPN13, PTPRE, and PTPRD, was significantly downregulated in NSCLC cell lines (p = 0.024). Both groups hypothesized that these genes may act as tumor suppressors. 11,12 Considering the role of PTPRF in the modulation of EGFR signaling and its carcinogenic potential, plus the use of EGFR-targeted therapy in metastatic NSCLC, a retrospective analysis was carried out to evaluate its potential as a predictive marker for treatment with erlotinib and to determine the prognostic role of PTPRF in NSCLC. This study is supported by the fact that PTPRF was found to be significantly differentially expressed by quantitative reverse transcription polymerase chain reaction on fresh-frozen and fixed material in Marker Identification Trial (MERIT, later described as the discovery cohort), a study designed to evaluate markers associated with erlotinib efficacy in metastatic NSCLC patients who had failed first-line chemotherapy. In that study, PTPRF was specifically interesting as it was one of the five markers most associated with clinical efficacy. It was decided to further investigate this marker before the others because of its higher association with clinical efficacy with a differential expression factor of more than five, and because it was potentially linked to the EGFR signaling pathway without specifically addressing the target gene (EGFR). MATERIALS AND METHODS Clinical Study Designs MERIT study (discovery cohort) The MERIT was a phase II, nonrandomized, gene expression profiling study conducted at 26 centers across 12 countries. A total of 264 eligible patients were enrolled and received oral erlotinib (150 mg/d) until progression, unacceptable toxicity, or death. Full methodology has been reported previously in the primary publication. 14 The main end point of the study was to correlate response to markers that were differentially expressed by a factor of eight. No marker meeting this criterion was identified. Other markers were sought in the database through additional exploratory analyses, to identify potential genes of interest for further research. EGFR, PSPH, RAPGEF5, and PTPRF were among the markers most strongly associated with clinical benefit. 14 SATURN study (validation cohort) The Sequential Tarceva in Unresectable NSCLC (SATURN) study was an international, phase III, randomized, placebo-controlled study to assess the efficacy and safety of maintenance erlotinib after first-line platinum-doublet chemotherapy. For this study, 1949 eligible patients received four cycles of first-line chemotherapy during the run-in phase, following which those without disease progression who had adequate performance status and good hematologic/renal/ hepatic function (n = 889) were randomized to receive maintenance erlotinib (orally, 150 mg/d) or placebo until progression, unacceptable toxicity or death. The full methodology has been reported previously. 4 Provision of a tumor sample was mandatory for SATURN, and extensive biomarker analyses have been conducted and reported. 15 Further exploratory analyses were performed based on previous observations from MERIT. Biomarker Assessment Methodology Exploratory analyses were conducted on material extracted from existing formalin-fixed, paraffin-embedded samples. For MERIT, RNA was extracted using the RNeasy Mini Kit (QIAGEN GmbH, Hilden, Germany). For SATURN, protocols and processing instructions developed by Roche Diagnostics (Penzberg, Germany) were followed. Quantitative reverse transcription polymerase chain reaction was then used to assess the prognostic and predictive value of marker gene expression levels, including PTPRF. High versus low levels of expression were dichotomized using the median, ie, high: greater than or equal to median and low: less than median with the housekeeping gene B2M being used as a control comparator. The methodology used was as previously described for similar gene expression analyses in the relevant studies. 14,15 Statistical Methodology For MERIT, hazard ratios (HRs) were estimated using Kaplan Meier methodology, with statistical significance expressed as p values using Wald s test. For SATURN, HRs were estimated using Kaplan Meier methodology, with interaction p values based on a Cox proportional hazard model. Treatment (erlotinib versus placebo), PTPRF expression level (high versus low), and treatment PTPRF level interaction were used as covariates for this analysis. Subgroup analysis in the population of patients previously identified as EGFR wild type was also performed, as this is the population for whom new predictive markers are required. As retrospective analyses of small patient subgroups, these analyses are not powered to demonstrate statistical significance but may identify trends. RESULTS MERIT Study (Discovery Cohort) In total, 102 representative samples were available for analysis of PTPRF gene expression; baseline characteristics were well balanced between the PTPRF subgroups (Table 1). In an exploratory ranking of genes based on their association with clinical benefit, PTPRF was in the top five, although formal statistical significance was not reached after correction for multiple testing. Examination of PFS and overall survival (OS) relative to PTPRF expression level suggested a differential effect (Fig. 1), but it was impossible to distinguish between the 1365
3 Soulières et al. Journal of Thoracic Oncology Volume 10, Number 9, September 2015 TABLE 1. Key Baseline Characteristics of the SATURN Validation Cohort by PTPRF Expression Characteristic SATURN Validation Cohort PTPRF High (n = 131) PTPRF Low (n = 131) Median age, yr (range) 60 (44 83) 59 (35 82) P value Gender, n (%) Male 103 (79) 86 (66) Female 28 (21) 45 (34) P value ECOG PS, n (%) 0 40 (31) 45 (34) 1 91 (69) 86 (66) P value Histology, n (%) Adenocarcinoma 45 (34) 80 (61) Squamous 78 (60) 36 (27) Other 8 (6) 15 (11) P value <0.001 Smoking status, n (%) Current smoker 86 (66) 65 (50) Former smoker 27 (21) 37 (28) Never smoker 18 (14) 29 (22) P value EGFR mutation status, n (%) Activating mutation 13 (10) 15 (11) Wild type 104 (79) 93 (71) Resistance mutation 0 (0) 1 (1) Indeterminate/missing/other 14 (11) 22 (17) P value SATURN, Sequential Tarceva in Unresectable NSCLC; EGFR, epidermal growth factor receptor; PTPRF, protein tyrosine phosphatase receptor type F; ECOG PS, Eastern Cooperative Oncology Group performance status. prognostic and predictive values of the marker in this singlearm study. Further validation was performed in SATURN. SATURN Study (Validation Cohort) Samples were available from 262 patients for PTPRF analysis. The population for whom PTPRF expression level was analyzed was representative of the overall study population (Supplementary Table 1, Supplemental Digital Content 1, and the subgroups were well balanced (Table 1); the results are, therefore, unlikely to be affected by sampling bias. PFS was improved with erlotinib versus placebo in the subgroup with high PTPRF expression (PTPRF high; HR, 0.47, 95% confidence interval [CI], ) and a difference was also noted in the subgroup with low PTPRF expression (PTPRF low; HR, 0.77, 95% CI, ; Fig. 2), although the CI for the latter subgroup did exceed 1.0. The treatment by PTPRF level interaction p value for PTPRF high versus PTPRF low was 0.06, showing a trend toward statistical significance. OS also was improved with erlotinib versus placebo in the PTPRF high subgroup (HR, 0.45, 95% CI, ), but there was a negligible difference in the PTPRF low subgroup (HR, 0.96, 95% CI, ; Fig. 3). The treatment by PTPRF level interaction p value was significant (p = 0.02). Examining the PFS and OS outcomes for the placebo group demonstrates that high PTPRF expression is a potential prognostic marker for shorter OS (respectively, p = 0.06 and p = 0.01; Fig. 4). Analysis in the confirmed EGFR wild-type population found similar results for PFS and OS in the PTPRF high versus PTPRF low subgroups (Fig. 5), suggesting that PTPRF expression is an independent marker for erlotinib treatment outcomes, rather than a surrogate for mutation status. When the data were adjusted for clinical covariates (gender, histology, Eastern Cooperative Oncology Group performance status), HRs for PFS were 0.48 (95% CI, ) in the PTPRF high group and 0.78 (95% CI, ) in the PTPRF low group, with an interaction p value of For OS, the HRs were 0.44 (95% CI, ) and 0.96 (95% CI, ), respectively, with a significant interaction p value of Further exploratory analyses from additional studies are included as Supplementary material (Supplemental Digital Content 2, DISCUSSION The MERIT study was initiated to generate hypotheses on factors associated with the efficacy of erlotinib. It was a single-arm study, and the results were of sufficiently significant interest for some genes found to be differentially expressed, including PTPRF, to test the prognostic, but more importantly predictive value, in a cohort randomized to erlotinib or placebo. However, it must be noted that these analyses were unplanned and should be considered as hypothesis generating until further validation is obtained. On the basis of the results from the translational analyses presented in this article of specimens obtained from clinical studies of erlotinib in patients with advanced NSCLC, PTPRF expression above the median appears to be a negative prognostic factor for OS in patients who have completed first-line therapy and for whom treatment with erlotinib is envisioned, although no prognostic influence on PFS could be discerned. This may be because of crossover, whereby the predictive effect of PTPRF expression is lost in the analysis of OS, whereas the prognostic effect, which is independent of treatment, remains identifiable. To confirm the prognostic value of PTPRF expression, however, we will require large cohorts of patients receiving multiple types and lines of therapies and evaluated in multivariate analysis considering other currently known prognostic factors. The presented analysis also suggests the hypothesis that PTPRF expression above the median may be a positive predictive factor for erlotinib treatment, regardless of EGFR mutation status. Further research could help to elucidate the mechanism by which PTPRF may influence erlotinib outcomes in lung cancer. If PTPRF expression is indeed independent of EGFR mutation status, as suggested by the wild-type results in this analysis, it may have value as a potential predictive marker for erlotinib 1366
4 Journal of Thoracic Oncology Volume 10, Number 9, September 2015 PTPRF Expression as a Marker for Erlotinib in NSCLC FIGURE 1. Progression-free survival (PFS, A) and overall survival (OS, B) relative to protein tyrosine phosphatase receptor type F (PTPRF) expression levels in the Marker Identification Trial (MERIT; quantitative reverse transcription polymerase chain reaction data). FIGURE 2. Progression-free survival (PFS) relative to protein tyrosine phosphatase receptor type F (PTPRF) high (A) and PTPRF low (B) status for erlotinib versus placebo in Sequential Tarceva in Unresectable NSCLC (SATURN). FIGURE 3. Overall survival (OS) relative to protein tyrosine phosphatase receptor type F (PTPRF) high (A) and PTPRF low (B) status for erlotinib versus placebo in Sequential Tarceva in Unresectable NSCLC (SATURN). 1367
5 Soulières et al. Journal of Thoracic Oncology Volume 10, Number 9, September 2015 FIGURE 4. Progression-free survival (PFS, A) and overall survival (OS, B) relative to protein tyrosine phosphatase receptor type F (PTPRF) status in the placebo group. HR, hazard ratio; CI, confidence interval. FIGURE 5. Progression-free survival (PFS, A) and overall survival (OS, B) relative to protein tyrosine phosphatase receptor type F (PTPRF) status in the epidermal growth factor receptor (EGFR) wild-type group. 1368
6 Journal of Thoracic Oncology Volume 10, Number 9, September 2015 PTPRF Expression as a Marker for Erlotinib in NSCLC treatment in advanced wild-type NSCLC. Indeed, this could be the first predictive marker to offer clinical efficacy in restricting erlotinib treatment to those patients most likely to have high clinical benefit and could also identify a population that does not seem to derive benefit from erlotinib therapy. However, further studies would be needed to validate PTPRF as a biomarker in the clinical setting, with the determination of a set level of expression as a cutoff rather than the median, to allow for a test that could be administered consistently between different laboratories and across different sample types. With the knowledge currently available, targeted therapy for NSCLC based on gene alterations linked with oncogenic addiction represents less than 20% of patients, although the advent of next-generation sequencing may identify as yet unknown alterations in a higher percentage of patients. 16 In the meantime, additional biomarkers are still required to guide treatment choice for all other patients for whom treatment with an EGFR inhibitor is considered. The results reported here indicate that PTPRF expression in two cohorts of patients presents a marker of significant interest and should be the object of further studies to provide more guidance on the use of erlotinib therapy in metastatic NSCLC. REFERENCES 1. Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, firstline study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011;29: Rosell R, Carcereny E, Gervais R, et al.; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13: Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013;31: Cappuzzo F, Ciuleanu T, Stelmakh L, et al.; SATURN investigators. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010;11: Zhu CQ, da Cunha Santos G, Ding K, et al.; National Cancer Institute of Canada Clinical Trials Group Study BR.21. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008;26: Hashimoto N, Zhang WR, Goldstein BJ. Insulin receptor and epidermal growth factor receptor dephosphorylation by three major rat liver protein-tyrosine phosphatases expressed in a recombinant bacterial system. Biochem J 1992;284 (Pt 2): Kulas DT, Goldstein BJ, Mooney RA. The transmembrane protein-tyrosine phosphatase LAR modulates signaling by multiple receptor tyrosine kinases. J Biol Chem 1996;271: Müller T, Choidas A, Reichmann E, Ullrich A. Phosphorylation and free pool of beta-catenin are regulated by tyrosine kinases and tyrosine phosphatases during epithelial cell migration. J Biol Chem 1999;274: Du WW, Fang L, Li M, et al. MicroRNA mir-24 enhances tumor invasion and metastasis by targeting PTPN9 and PTPRF to promote EGF signaling. J Cell Sci 2013;126(Pt 6): Whitmore TE, Peterson A, Holzman T, et al. Integrative analysis of N-linked human glycoproteomic data sets reveals PTPRF ectodomain as a novel plasma biomarker candidate for prostate cancer. J Proteome Res 2012;11: Motiwala T, Kutay H, Ghoshal K, et al. Protein tyrosine phosphatase receptor-type O (PTPRO) exhibits characteristics of a candidate tumor suppressor in human lung cancer. Proc Natl Acad Sci U S A 2004;101: Scrima M, De Marco C, De Vita F, et al. The nonreceptor-type tyrosine phosphatase PTPN13 is a tumor suppressor gene in non-small cell lung cancer. Am J Pathol 2012;180: Alonso A, Sasin J, Bottini N, et al. Protein tyrosine phosphatases in the human genome. Cell 2004;117: Tan EH, Ramlau R, Pluzanska A, et al. A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer. Ann Oncol 2010;21: Brugger W, Triller N, Blasinska-Morawiec M, et al. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol 2011;29: Drilon A, Wang L, Arcila ME, et al. Broad, hybrid capture-based nextgeneration sequencing identifies actionable genomic alterations in lung adenocarcinomas otherwise negative for such alterations by other genomic testing approaches. Clin Cancer Res 2015 [Epub ahead of print]. 1369
EGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients with Postsurgical Recurrence
102 Journal of Cancer Research Updates, 2012, 1, 102-107 EGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients with Postsurgical Recurrence Kenichi
More informationLudger Sellmann 1, Klaus Fenchel 2, Wolfram C. M. Dempke 3,4. Editorial
Editorial Improved overall survival following tyrosine kinase inhibitor treatment in advanced or metastatic non-small-cell lung cancer the Holy Grail in cancer treatment? Ludger Sellmann 1, Klaus Fenchel
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Erlotinib for the third or fourth-line treatment of NSCLC January 2012
Disease background LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Erlotinib for the third or fourth-line treatment of NSCLC January 2012 Lung cancer is the second most common cancer in the UK (after breast),
More informationPROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC. Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy
PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy Prognostic versus predictive Prognostic: In presence of the biomarker patient outcome
More informationKeywords: non-small-cell lung cancer; EGFR; biomarkers; gene expression; FISH; ReadMax
The Journal of Pathology: Clinical Research Published online 31 January 2015 in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/cjp2.15 ReadMax a novel reading and scoring approach for EGFR
More informationRetrospective analysis of Gefitinib and Erlotinib in EGFR-mutated non-small-cell lung cancer patients
(2017) 1(1): 16-24 Mini Review Open Access Retrospective analysis of Gefitinib and Erlotinib in EGFR-mutated non-small-cell lung cancer patients Chao Pui I 1,3, Cheng Gregory 1, Zhang Lunqing 2, Lo Iek
More information2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University
2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling
More informationJoachim Aerts Erasmus MC Rotterdam, Netherlands. Drawing the map: molecular characterization of NSCLC
Joachim Aerts Erasmus MC Rotterdam, Netherlands Drawing the map: molecular characterization of NSCLC Disclosures Honoraria for advisory board/consultancy/speakers fee Eli Lilly Roche Boehringer Ingelheim
More informationBiomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007
Biomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007 Bruce E. Johnson, MD Dana-Farber Cancer Institute, Brigham and Women s Hospital, and Harvard
More informationOverall survival with afatinib versus chemotherapy in patients with NSCLC harboring common EGFR
Overall survival with afatinib versus chemotherapy in patients with NSCLC harboring common EGFR mutations: subgroup analyses by race/ethnicity in LUX-Lung 3 and LUX-Lung 6 Yi-Long Wu, 1 Lecia V Sequist,
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationOUR EXPERIENCES WITH ERLOTINIB IN SECOND AND THIRD LINE TREATMENT PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER
& OUR EXPERIENCES WITH ERLOTINIB IN SECOND AND THIRD LINE TREATMENT PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER Interim Data Report of TRUST study on patients from Bosnia and Herzegovina
More informationEGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS
EGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS Federico Cappuzzo Istituto Clinico Humanitas IRCCS Rozzano-Italy The EGFR/HER Family Ligand binding domain
More informationMolecular Targets in Lung Cancer
Molecular Targets in Lung Cancer Robert Ramirez, DO, FACP Thoracic and Neuroendocrine Oncology November 18 th, 2016 Disclosures Consulting and speaker fees for Ipsen Pharmaceuticals, AstraZeneca and Merck
More informationChanging demographics of smoking and its effects during therapy
Changing demographics of smoking and its effects during therapy Egbert F. Smit MD PhD. Dept. Pulmonary Diseases, Vrije Universiteit Medical Centre, Amsterdam, The Netherlands Smoking prevalence adults
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationSlide 1. Slide 2 Maintenance Therapy Options. Slide 3. Maintenance Therapy in the Management of Non-Small Cell Lung Cancer. Maintenance Chemotherapy
Slide 1 Maintenance Therapy in the Management of Non-Small Cell Lung Cancer Frances A Shepherd, MD FRCPC Scott Taylor Chair in Lung Cancer Research Princess Margaret Hospital, Professor of Medicine, University
More informationImproving outcomes for NSCLC patients with brain metastases
Improving outcomes for NSCLC patients with brain metastases Martin Schuler West German Cancer Center, Essen, Germany In Switzerland, afatinib is approved as monotherapy for patients with non-small cell
More informationHistologic classification of non-small-cell lung cancer over time: reducing the rates of not-otherwise-specified
ORIGINAL ARTICLE Histologic classification of non-small-cell lung cancer over time: reducing the rates of not-otherwise-specified C. Ho md,* K.M. Tong bsc,* K. Ramsden bsc,* D.N. Ionescu md, and J. Laskin
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and Manchester University Hospital Manchester, UK Outline Data on first-line Overcoming T790M mutation
More informationErlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy
Erlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy September 2008 This technology summary is based on information available at the time of research and a
More informationSurvival of patients with advanced lung adenocarcinoma before and after approved use of gefitinib in China
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Survival of patients with advanced lung adenocarcinoma before and after approved use of gefitinib in China Yu-Tao Liu, Xue-Zhi Hao, Jun-Ling Li, Xing-Sheng
More informationIntroduction ORIGINAL ARTICLE
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Survival analysis of patients with advanced non-small cell lung cancer receiving tyrosine kinase inhibitor (TKI) treatment: A multi-center retrospective
More informationCorrespondence should be addressed to Kumar Prabhash;
Hindawi Chemotherapy Research and Practice Volume 2017, Article ID 8196434, 4 pages https://doi.org/10.1155/2017/8196434 Clinical Study Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating
More informationTechnology appraisal guidance Published: 29 June 2011 nice.org.uk/guidance/ta227
Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer Technology appraisal guidance Published: 29 June 2011 nice.org.uk/guidance/ta227 NICE 2018. All rights reserved. Subject to
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Data on first-line Overcoming T790M
More informationK-Ras signalling in NSCLC
Targeting the Ras-Raf-Mek-Erk pathway Egbert F. Smit MD PhD Dept. Pulmonary Diseases Vrije Universiteit VU Medical Centre Amsterdam, The Netherlands K-Ras signalling in NSCLC Sun et al. Nature Rev. Cancer
More informationFirst line erlotinib for NSCLC patients not selected by EGFR mutation: keep carrying the TORCH or time to let the flame die?
Perspective First line erlotinib for NSCLC patients not selected by EGFR mutation: keep carrying the TORCH or time to let the flame die? Jared Weiss Multidisciplinary Thoracic Oncology Program, Lineberger
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationFollow this and additional works at:
Washington University School of Medicine Digital Commons@Becker Open Access Publications 2015 Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell
More informationCorporate Medical Policy
Corporate Medical Policy Proteomic Testing for Targeted Therapy in Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: proteomic_testing_for_targeted_therapy_in_non_small_cell_lung_cancer
More informationFrequency of Epidermal Growth Factor Mutation Status and Its Effect on Outcome of Patients with Adenocarcinoma of the Lung
Journal of Cancer Therapy, 2014, 5, 1012-1020 Published Online September 2014 in SciRes. http://www.scirp.org/journal/jct http://dx.doi.org/10.4236/jct.2014.511106 Frequency of Epidermal Growth Factor
More informationIRESSA (Gefitinib) The Journey. Anne De Bock Portfolio Leader, Oncology/Infection European Regulatory Affairs AstraZeneca
IRESSA (Gefitinib) The Journey Anne De Bock Portfolio Leader, Oncology/Infection European Regulatory Affairs AstraZeneca Overview The Drug The Biomarker and Clinical Trials Sampling Lessons Learned The
More informationApproach to biomarker testing: perspectives from various specialties
ORIGINAL ARTICLE Approach to biomarker testing: perspectives from various specialties M.R. Sung bsc,* P.M. Ellis md, S. Verma md, E. Duncan, and N.B. Leighl md mmsc* ABSTRACT Background Despite its importance
More informationMaintenance Therapy for Advanced NSCLC: Which Patients, Which Approach?
Maintenance Therapy for Advanced NSCLC: Which Patients, Which Approach? Mark A. Socinski, MD Visiting Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology
More informationMAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf
MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf OUTLINE Background and Concept Switch Maintenance Continuation Maintenance
More informationAntiangiogenic Agents in NSCLC Where are we? Which biomarkers? VEGF Is the Only Angiogenic Factor Present Throughout the Tumor Life Cycle
Antiangiogenic Agents in NSCLC Where are we? Which biomarkers? Martin Reck Department e t of Thoracic c Oncology ogy Hospital Grosshansdorf Germany VEGF Is the Only Angiogenic Factor Present Throughout
More informationVirtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer.
Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer Reference Slides ALK Rearrangement in NSCLC ALK (anaplastic lymphoma kinase) is a receptor
More informationEGFR MUTATIONS IN NON SMALL CELL LUNG CANCER PATIENTS IN SOUTH AFRICA
EGFR MUTATIONS IN NON SMALL CELL LUNG CANCER PATIENTS IN SOUTH AFRICA Sze Wai Chan A research report submitted to the Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, in partial
More informationMaintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
More informationRefining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis
5/17/13 Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis Johannes Kratz, MD Post-doctoral Fellow, Thoracic Oncology Laboratory
More informationLung cancer is the leading cause of cancer related death
Original Article Bcl-2-Like Protein 11 Deletion Polymorphism Predicts Survival in Advanced Non Small-Cell Lung Cancer Jih-Hsiang Lee, MD,* Yu-Lin Lin, MD,* Wei-Hsun Hsu, MD,* Hsuan-Yu Chen, PhD, # Yeun-Chung
More informationErlotinib for the first-line treatment of EGFR-TK mutation positive non-small cell lung cancer
ERRATUM Erlotinib for the first-line treatment of EGFR-TK mutation positive non-small cell lung cancer This report was commissioned by the NIHR HTA Programme as project number 11/08 Completed 6 th January
More informationThe phase III FLEX study showed that the addition of
Original Article Relationship Between EGFR Expression, EGFR Mutation Status, and the Efficacy of Chemotherapy Plus Cetuximab in FLEX Study Patients with Advanced Non Small-Cell Lung Cancer Jean-Yves Douillard,
More informationD Ross Camidge, MD, PhD
i n t e r v i e w D Ross Camidge, MD, PhD Dr Camidge is Director of the Thoracic Oncology Clinical Program and Associate Director for Clinical Research at the University of Colorado Cancer Center in Aurora,
More informationPersonalized Medicine in Oncology and the Implication for Clinical Development
THE POWER OFx Experts. Experienc e. Execution. Personalized Medicine in Oncology and the Implication for Clinical Development Jamal Gasmi MD, PhD, Medical Director, Medpace Introduction The notable success
More informationORIGINAL ARTICLE. Oncology and Translational Medicine DOI /s Abstract
Oncology and Translational Medicine DOI 10.1007/s10330-018-0281-1 August 2018, Vol. 4, No. 4, P158 P162 ORIGINAL ARTICLE Treatment and survival status of patients with EGFR mutation-positive stage IV lung
More informationThe Evolving Role of Molecular Markers in Managing Non-Small Cell Lung Cancer
The Evolving Role of Molecular Markers in Managing Non-Small Cell Lung Cancer Nathan A. Pennell, M.D., Ph.D. Assistant Professor Solid Tumor Oncology Cleveland Clinic Taussig Cancer Institute www.cancergrace.org
More informationPRACTICE GUIDELINE SERIES
ELLIS et al. PRACTICE GUIDELINE SERIES The role of the epidermal growth factor receptor tyrosine kinase inhibitors as therapy for advanced, metastatic, and recurrent nonsmall-cell lung cancer: a Canadian
More informationComparison of Gefitinib versus Docetaxel in Patients with Pre-Treated Non-Small Cell Lung Cancer (NSCLC)
J Lung Cancer 2009;8(2):61-66 Comparison of Gefitinib versus Docetaxel in Patients with Pre-Treated Non-Small Cell Lung Cancer (NSCLC) More effective treatments in first, second, and third-line of metastatic
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More informationPersonalized maintenance therapy in advanced non-small cell lung cancer
China Lung Cancer Research Highlight Personalized maintenance therapy in advanced non-small cell lung cancer Kazuhiro Asami, Kyoichi Okishio, Tomoya Kawaguchi, Shinji Atagi Department of Clinical Oncology,
More informationOriginal Article. Abstract
Japanese Journal of Clinical Oncology, 2015, 45(7) 670 676 doi: 10.1093/jjco/hyv054 Advance Access Publication Date: 15 April 2015 Original Article Original Article Efficacy of chemotherapy after first-line
More informationEGFR-directed monoclonal antibodies in non-small cell lung cancer: how to predict efficacy?
Review Article EGFR-directed monoclonal antibodies in non-small cell lung cancer: how to predict efficacy? Robert Pirker Department of Medicine I, Medical University of Vienna, 1090 Vienna, Austria Corresponding
More informationEditorial Process: Submission:10/27/2017 Acceptance:05/25/2018
DOI:10.22034/APJCP.2018.19.7.1761 TKI by Liquid Biopsy RESEARCH ARTICLE Editorial Process: Submission:10/27/2017 Acceptance:05/25/2018 A Case-control Study Supporting the Use of Liquid Biopsy in the Targeted
More informationDetection of Anaplastic Lymphoma Kinase (ALK) gene in Non-Small Cell lung Cancer (NSCLC) By CISH Technique
Cancer and Clinical Oncology; Vol. 7, No. 1; 2018 ISSN 1927-4858 E-ISSN 1927-4866 Published by Canadian Center of Science and Education Detection of Anaplastic Lymphoma Kinase (ALK) gene in Non-Small Cell
More informationRatio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer
Original Article Ratio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer Fangfang Chen 1 *, Yanwen Yao 2 *, Chunyan
More informationMutation and prognostic analyses of PIK3CA in patients with completely resected lung adenocarcinoma
Cancer Medicine ORIGINAL RESEARCH Open Access Mutation and prognostic analyses of PIK3CA in patients with completely resected lung adenocarcinoma Zhengbo Song 1,2, Xinmin Yu 1 & Yiping Zhang 1,2 1 Department
More informationMedia Release. Basel, 07 December 2017
Media Release Basel, 07 December 2017 Phase III IMpower150 study showed Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapy reduced the risk of disease worsening or death by 38 percent
More informationAURA 3: the last word on chemotherapy as a control arm in EGFR mutant NSCLC?
Editorial Page 1 of 5 AURA 3: the last word on chemotherapy as a control arm in EGFR mutant NSCLC? Terry L. Ng, D. Ross Camidge Division of Medical Oncology, Department of Medicine, University of Colorado
More informationPage: 1 of 27. Molecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer
Last Review Status/Date: December 2014 Page: 1 of 27 Non-Small-Cell Lung Cancer Description Over half of patients with non-small-cell lung cancer (NSCLC) present with advanced and therefore incurable disease,
More informationPersonalized Medicine: Lung Biopsy and Tumor
Personalized Medicine: Lung Biopsy and Tumor Mutation Testing Elizabeth H. Moore, MD Personalized Medicine: Lung Biopsy and Tumor Mutation Testing Genomic testing has resulted in a paradigm shift in the
More informationLung cancer represents the leading cause of death from
ORIGINAL ARTICLE Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Beyond Progressive Disease A Retrospective Analysis for Japanese Patients with Activating EGFR Mutations Kenichi Nishie, MD,*
More informationRe-Submission. Scottish Medicines Consortium. erlotinib, 100 and 150mg film-coated tablets (Tarceva ) No. 220/05 Roche. 5 May 2006
Scottish Medicines Consortium Re-Submission erlotinib, 100 and 150mg film-coated tablets (Tarceva ) No. 220/05 Roche 5 May 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationSupplementary Online Content
Supplementary Online Content Mezquita L, Auclin E, Ferrara R, et al. Association of the Lung Immune Prognostic Index with immune checkpoint inhibitor outcomes in patients with advanced non small cell lung
More informationCancer Cell Research 14 (2017)
Available at http:// www.cancercellresearch.org ISSN 2161-2609 Efficacy and safety of bevacizumab for patients with advanced non-small cell lung cancer Ping Xu, Hongmei Li*, Xiaoyan Zhang Department of
More informationRESEARCH ARTICLE. Ryosuke Hirano 1, Junji Uchino 1 *, Miho Ueno 2, Masaki Fujita 1, Kentaro Watanabe 1. Abstract. Introduction
RESEARCH ARTICLE Low-dose Epidermal Growth Factor Receptor (EGFR)- Tyrosine Kinase Inhibition of EGFR Mutation-positive Lung Cancer: Therapeutic Benefits and Associations Between Dosage, Efficacy and Body
More informationTest Category: Prognostic and Predictive. Clinical Scenario
Use of Epidermal Growth Factor Receptor (EGFR) Mutation Analysis in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) to Determine Erlotinib Use as First-line Therapy Test Category: Prognostic
More informationNSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
More information11/21/2009. Erlotinib in KRAS Mt patients. Bevacizumab in Squamous patients
Decision-Making in Non-Small Cell Lung Cancer (NSCLC): Moving from Empiric to Personalized & Molecular-based Therapy David R. Gandara, MD University of California Davis Cancer Center Disclosures Research
More informationNivolumab: esperienze italiane nel carcinoma polmonare avanzato
NSCLC avanzato: quali novità nel 2018? Negrar, 30 Ottobre 2018 Nivolumab: esperienze italiane nel carcinoma polmonare avanzato Francesco Grossi UOC Oncologia Medica Fondazione IRCCS Ca Granda Ospedale
More informationDo You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement. Reference Slides Introduction
Do You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement Reference Slides Introduction EML4-ALK Fusion Oncogene Key Driver in 3% to 7% NSCLC Inversion or Translocation
More informationNational Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan;
Competing central nervous system or systemic progression analysis for patients with EGFR mutation-positive NSCLC receiving afatinib in LUX-Lung 3, 6, and 7 James C.-H. Yang, 1 Yi-Long Wu, 2 Vera Hirsh,
More informationLihong Ma 1 *, Zhengbo Song 2 *, Yong Song 1, Yiping Zhang 2. Original Article
Original Article MET overexpression coexisting with epidermal growth factor receptor mutation influence clinical efficacy of EGFR-tyrosine kinase inhibitors in lung adenocarcinoma patients Lihong Ma 1
More informationExploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Exploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) Suresh S. Ramalingam, MD Director of Thoracic Oncology Associate Professor Emory University Atlanta,
More informationBiomedical Research 2017; 28 (14): ISSN X
Biomedical Research 2017; 28 (14): ISSN 0970-938X www.biomedres.info Study of the relationship between EGFR mutation status and bone metastasis in advanced lung adenocarcinoma. Xiaoye Ai, Adalati Yasheng,
More informationProteomic Testing for Targeted Therapy in Non-Small-Cell Lung Cancer
Last Review Status/Date: December 2015 Page: 1 of 21 Small-Cell Lung Cancer Summary Proteomic testing has been proposed as a way to predict outcomes and response to and selection of targeted therapy for
More informationReflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer
Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual
More informationMolecular Analysis for Targeted Therapy for Non- Small-Cell Lung Cancer Section 2.0 Medicine Subsection 2.04 Pathology/Laboratory
2.04.45 Molecular Analysis for Targeted Therapy for Non- Small-Cell Lung Cancer Section 2.0 Medicine Subsection 2.04 Pathology/Laboratory Effective Date November 26, 2014 Original Policy Date November
More informationOsimertinib (lung cancer)
IQWiG Reports Commission No. A16-14 Osimertinib (lung cancer) Benefit assessment according to 35a Social Code Book V 1 Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Osimertinib
More informationPERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER Virginie Westeel Chest Disease Department University Hospital Besançon, France LEARNING OBJECTIVES 1. To understand the potential of perioperative
More informationPIK3CA mutations are found in approximately 7% of
Original Article Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas Juliana Eng, MD,*
More informationMaking the first decision: EGFR mutation-positive NSCLC in the advanced setting
ELCC May 217, Switzerland Making the first decision: EGFR mutation-positive NSCLC in the advanced setting Noemí Reguart, MD, PhD Hospital Clínic de Barcelona, Spain Disclosures Consultant or Advisory Role
More information7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview
Emerging mutations as predictive biomarkers in lung cancer: Overview Kirtee Raparia, MD Assistant Professor of Pathology Cancer Related Deaths: United States Men Lung and bronchus 28% Prostate 10% Colon
More informationOsamu Tetsu, MD, PhD Associate Professor Department of Otolaryngology-Head and Neck Surgery School of Medicine, University of California, San
Osamu Tetsu, MD, PhD Associate Professor Department of Otolaryngology-Head and Neck Surgery School of Medicine, University of California, San Francisco Lung Cancer Classification Pathological Classification
More informationRecent Advances in Lung Cancer: Updates from ASCO 2017
Recent Advances in Lung Cancer: Updates from ASCO 2017 Charu Aggarwal, MD, MPH Assistant Professor of Medicine Division of Hematology-Oncology Abramson Cancer Center University of Pennsylvania 6/15/2017
More informationVeriStrat Poor Patients Show Encouraging Overall Survival and Progression Free Survival Signal; Confirmatory Phase 2 Study Planned by Year-End
AVEO and Biodesix Announce Exploratory Analysis of VeriStrat-Selected Patients with Non-Small Cell Lung Cancer in Phase 2 Study of Ficlatuzumab Presented at ESMO 2014 Congress VeriStrat Poor Patients Show
More informationBone Metastases and the EGFR and KRAS Mutation Status in Lung Adenocarcinoma - The Results of Three Year Retrospective Analysis
Pathol. Oncol. Res. DOI 10.1007/s12253-015-9955-2 RESEARCH Bone Metastases and the EGFR and KRAS Mutation Status in Lung Adenocarcinoma - The Results of Three Year Retrospective Analysis Nóra Bittner 1
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationFEP Medical Policy Manual
FEP Medical Policy Manual Effective Date: April 15, 2018 Related Policies: 2.04.62 Proteomics-Based Testing Related to Ovarian Proteomic Testing for Targeted Therapy in Non-Small-Cell Lung Description
More informationThe Efficacy and Safety of Platinum/Vinorelbine as More Than Second-Line Chemotherapy for Advanced Non-small Cell Lung Cancer
pissn 1598-2998, eissn 2005-9256 Cancer Res Treat. 2015;47(4):638-644 Original Article http://dx.doi.org/10.4143/crt.2014.316 Open Access The Efficacy and Safety of Platinum/Vinorelbine as More Than Second-Line
More informationManagement Strategies for Lung Cancer Sensitive or Resistant to EGRF Inhibitors
Management Strategies for Lung Cancer Sensitive or Resistant to EGRF Inhibitors Conor E. Steuer, MD Assistant Professor The Winship Cancer Institute of Emory University July 27, 2017 1 Lung Cancer One
More informationResearch Article Mutated KRAS is an Independent Negative Prognostic Factor for Survival in NSCLC Stage III Disease Treated with High-Dose Radiotherapy
Lung Cancer International Volume 2012, Article ID 587424, 6 pages doi:10.1155/2012/587424 Research Article Mutated KRAS is an Independent Negative Prognostic Factor for Survival in NSCLC Stage III Disease
More informationMedia Release. Basel, 17 May 2018
Media Release Basel, 17 May 2018 Phase III IMpower150 study showed Roche s Tecentriq and Avastin plus carboplatin and paclitaxel helped people with a specific type of metastatic lung cancer live significantly
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More informationAfatinib in patients with EGFR mutation-positive NSCLC harboring uncommon mutations: overview of clinical data
Afatinib in patients with EGFR mutation-positive NSCLC harboring uncommon mutations: overview of clinical data Oscar Arrieta, 1 Pedro De Marchi, 2 Nobuyuki Yamamoto, 3 Chong-Jen Yu, 4 Sai-Hong I Ou, 5
More informationSupplementary Online Content
Supplementary Online Content Kris MG, Johnson BE, Berry LD, et al. Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs. JAMA. doi:10.1001/jama.2014.3741 etable 1. Trials
More information